- Review
- Open Access
- Published:
The role of the Tei index in assessing for cardiotoxicity from anthracycline chemotherapy: a systematic review
Echo Research & Practice volume 8, pages R1–R11 (2021)
Abstract
Background Anthracycline agents are known to be effective in treating tumors and hematological malignancies. Although these agents improve survival, their use is associated with cardiotoxic effects, which most commonly manifests as left ventricular systolic dysfunction (LVSD). As such, guidelines recommend the periodic assessment of left ventricular ejection fraction (LVEF). However, as diastolic dysfunction likely proceeds systolic impairment in this setting, the role of Tei index may offer additional benefit in detecting subclinical LVSD.
Methods We conducted a systematic review to investigate the evidence for the use of Tei index in assessing subclinical cardiotoxicity in patients receiving anticancer agents. A search of Medline and EMBASE was performed and relevant studies were reviewed and narratively synthesized.
Results A total of 13 studies were included with a total of 800 patients (mean age range 46-62 years, percentage of male participants ranged from 0-86.9%). An increase in Tei index was observed in 11 studies, which suggested a decline in cardiac function following chemotherapy. Out of these, six studies indicated that the Tei index is a useful parameter in predicting cardiotoxic LVSD. Furthermore, five studies indicated Tei index to be superior to LVEF in detecting subclinical cardiotoxicity.
Conclusions Though there are some studies that suggest that Tei index may be a useful indicator in assessing subclinical anthracycline-related cardiotoxicity, the findings are inconsistent and so more studies are needed before the evaluation of Tei index is performed routinely in patients receiving chemotherapy.
Conclusions Though there are some studies that suggest that Tei index may be a useful indicator in assessing subclinical anthracycline-related cardiotoxicity, the findings are inconsistent and so more studies are needed before the evaluation of Tei index is performed routinely in patients receiving chemotherapy.
References
Dodos F, Halbsguth T, Erdman E & Hoppe UC Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clinical Research in Cardiology 2008 97 318–326. (https://doi.org/10.1007/s00392-007-0633-6)
Giordano SH, Lin YL, Kuo YF, Hortobagyi GN & Goodwin JS Decline in the use of anthracyclines for breast cancer. Journal of Clinical Oncology 2012 30 2232–2239. (https://doi.org/10.1200/JCO.2011.40.1273)
Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, Friedberg JW, Zelenetz AD, Maurer MJ, Cerhan JR, et al. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. British Journal of Haematology 2015 170 85–95. (https://doi.org/10.1111/bjh.13399)
Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, et al. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 2016 122 3145–3151. (https://doi.org/10.1002/cncr.30173)
Chung R, Ghosh AK & Banerjee A Cardiotoxicity: precision medicine with imprecise definitions. Open Heart 2018 5 e000774. (https://doi.org/10.1136/openhrt-2018-000774)
Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, Gosavi S, Carver JR, Wiegers SE, Martin RP, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. American Journal of Cardiology 2011 107 1375–1380. (https://doi.org/10.1016/j.amjcard.2011.01.006)
Zamorano JL, Lancelloti P, Munoz DR, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspies of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal 2016 37 2768–2801.(https://doi.org/10.1093/eurheartj/ehw211)
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging 2015 16 233–270. (https://doi.org/10.1093/ehjci/jev014)
Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A, Coudert B, Cottin Y, Fumoleau P & Brunotte F Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Research and Treatment 2011 130 845–854. (https://doi.org/10.1007/s10549-011-1714-9)
Cikes M & Solomon SD Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. European Heart Journal 2016 37 1642–1650. (https://doi.org/10.1093/eurheartj/ehv510)
Patel CD, Balakrishnan VB, Kumar L, Naswa N & Malhotra A Does left ventricular diastolic function deteriorate earlier than left ventricular systolic function in anthracycline cardiotoxicity? Hellenic Journal of Nuclear Medicine 2010 13 233–237.
Goroshi M & Chand D Myocardial performance index (Tei index): a simple tool to identify cardiac dysfunction in patients with diabetes mellitus. Indian Heart Journal 2016 68 83–87. (https://doi.org/10.1016/j.ihj.2015.06.022)
Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, Tajik AJ & Seward JB New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function-a study in normals and dilated cardiomyopathy. Journal of Cardiology 1995 26 357–366.
Ayhan SS, Ozdemir K, Kayrak M, Bacaksiz A, Vatankulu MA, Eren Ö, Koc F, Duman C, Gülec H, Demir K, et al. The evaluation of doxorubicin-induced cardiotoxicity: comparison of Doppler and tissue Doppler dervied myocardial performance index. Cardiology Journal 2012 19 363–368. (https://doi.org/10.5603/cj.2012.0066)
Belham M, Kruger A, Mepham S, Faganello G & Pritchard C Monitoring left ventricular function in adults receiving anthracycling-containing chemotherapy. European Journal of Heart Failure 2007 9 409–414. (https://doi.org/10.1016/j.ejheart.2006.09.007)
Rohde LE, Baldi A, Weber C, Geib G, Mazzotti NG, Fiorentini M, Roggia M, Pereira R & Clausell N Tei index in adult patients submitted to Adriamycin chemotherapy: failure to predict early systolic dysfunction. Diagnosis of adriamycin cardiotoxicity. International Journal of Cardiovascular Imaging 2007 23 185–191. (https://doi.org/10.1007/s10554-006-9145-0)
Di Lisi D, Bonura F, Macaione F, Peritore A, Meschisi M, Cuttitta F & Novo G, D’Alessandro N, Novo S Chemotherapy-induced cardiotoxicity: role of tissue Doppler in the early diagnosis of left ventricular dysfunction. Anti-Cancer Drugs 2011 22 468–472. (https://doi.org/10.1097/CAD.0b013e3283443704)
Dogru A, Cabuk D, Sahin T, Dolasik I, Temiz S & Uygun K Evaluation of cardiotoxicity via speckle tracking echocardiography in patients treated with anthracyclines. Onkologie 2013 36 712–716. (https://doi.org/10.1159/000356850)
Elalouani C, Benhmidoun MA, Rida H, AitRaiss M, Derhem N, Elomrani A, Khouchani M, Tahri A, Errehmouni A, Faouzi R, et al. Short and medium term cardiotoxicity of anthracyclins: a prospective study. Annales de Cardiologie et d’Angeiologie 2012 6 254–266.(https://doi.org/10.1016/j.ancard.2012.03.004)
Elbl L, Vasova I, Tomaskova I, Jedlicka F, Navratil M, Pospisil Z & Vorlicek J Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin’s lymphoma. Neoplasma 2006 53 174–181.
Erdoğan D, Yücel H, Alanoğlu EG, Uysal BA, Koçer M, Ozaydın M & Doğan A Can comprehensive echocardiographic evaluation provide an advantage to predict anthracycline-induced cardiomyopathy? Turk Kardiyoloji Dernegi Arsivi 2011 39 646–653. (https://doi.org/10.5543/tkda.2011.01700)
Mizia-Stec K, Gościńska A, Mizia M, Haberka M, Chmiel A, Poborski W & Gąsior Z Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodeling. Kardiologia Polska 2013 71 681–690. (https://doi.org/10.5603/KP.2013.0154)
Senju N, Ikeda S, Koga S, Miyahara Y, Tsukasaki K, Tomonaga M & Kohno S The echocardiographic Tei-index reflects early myocardial damage induced by anthracyclines in patients with hematological malignancies. Heart and Vessels 2007 22 393–397. (https://doi.org/10.1007/s00380-007-0985-x)
Shaikh AY, Suryadevara S, Tripathi A, Ahmed M, Kane JL, Escobar J, Cerny J, Nath R, McManus DD, Shih J, et al. Mitoxantrone-induced cardiotoxicity in acute myeloid leukemia - a velocity vector imaging analysis. Echocardiography 2016 33 1166–1177. (https://doi.org/10.1111/echo.13245)
Billingham M & Bristow M Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy. Cancer Treatment and Symptoms 1984 3 71–76.
Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM & Kupersmith J Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. Journal of the American College of Cardiology 1992 20 62–69. (https://doi.org/10.1016/0735-1097(9290138-d)
Mercuro G, Cadeddu C, Piras A, Dessì M, Madeddu C, Deidda M, Serpe R, Massa E & Mantovani G Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 2007 12 1124–1133. (https://doi.org/10.1634/theoncologist.12-9-1124)
Møller JE, Sondergaard E, Poulsen SH & Egstrup E The Doppler echocardiographic myocardial performance index predicts left-ventricular dilation and cardiac death after myocardial infarction. Cardiology 2001 92 105–111.(https://doi.org/10.1159/000047355)
Oikonomou EK, Kikkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D & Thavendiranathan P Assessment of prognostic valve od left ventricular global longitudinal strain for early prediction of chemotherapy induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiology 2019 4 1007–1018. (https://doi.org/10.1001/jamacardio.2019.2952)
Zhang CJ, Pei XL, Song FY, Guo Y, Zhang QL, Shu XH, Hsi DH & Cheng LLC Early anthracycline-induced cardiotoxicity monitored by echocardiographic Doppler parameters combined with serum hs-cTnT. Echocardiography 2017 34 1593–1600. (https://doi.org/10.1111/echo.13704)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the articles Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the articles Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Bennett, S., Cubukcu, A., Wong, C.W. et al. The role of the Tei index in assessing for cardiotoxicity from anthracycline chemotherapy: a systematic review. Echo Res Pract 8, R1–R11 (2021). https://doi.org/10.1530/ERP-20-0013
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1530/ERP-20-0013
Key Words
- myocardial performance index
- Tei index
- cardiotoxicity
- 2D echocardiography